| The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families MIW Achatz, M Olivier, F Le Calvez, G Martel-Planche, A Lopes, BM Rossi, ... Cancer letters 245 (1-2), 96-102, 2007 | 229 | 2007 |
| Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. P Ashton-Prolla, B Tong, J Shabbeer, KH Astrin, CM Eng, RJ Desnick Journal of investigative medicine: the official publication of the American …, 2000 | 175 | 2000 |
| Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect S Garritano, F Gemignani, EI Palmero, M Olivier, G Martel‐Planche, ... Human mutation 31 (2), 143-150, 2010 | 170 | 2010 |
| Thalidomide, a current teratogen in South America EE Castilla, P Ashton‐Prolla, E Barreda‐Mejia, D Brunoni, DP Cavalcanti, ... Teratology 54 (6), 273-277, 1996 | 153 | 1996 |
| TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review C Rosset, CBO Netto, P Ashton-Prolla Genetics and molecular biology 40 (1), 69-79, 2017 | 147 | 2017 |
| Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil EI Palmero, L Schüler-Faccini, M Caleffi, MIW Achatz, M Olivier, ... Cancer letters 261 (1), 21-25, 2008 | 134 | 2008 |
| Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome EI Palmero, MIW Achatz, P Ashton-Prolla, M Olivier, P Hainaut Current opinion in oncology 22 (1), 64-69, 2010 | 132 | 2010 |
| Genomic rearrangements in BRCA1 and BRCA2: A literature review IP Ewald, PLI Ribeiro, EI Palmero, SL Cossio, R Giugliani, ... Genetics and Molecular Biology 32, 437-446, 2009 | 125 | 2009 |
| An alternative protocol for DNA extraction from formalin fixed and paraffin wax embedded tissue R Coura, JC Prolla, L Meurer, P Ashton-Prolla Journal of Clinical Pathology 58 (8), 894-895, 2005 | 118 | 2005 |
| Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care P Ashton-Prolla, J Giacomazzi, AV Schmidt, FL Roth, EI Palmero, ... BMC cancer 9, 1-9, 2009 | 105 | 2009 |
| Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study L Schüler, A Pastuszak, MTV Sanseverino, IM Orioliz, D Brunoni, ... Reproductive Toxicology 13 (2), 147-151, 1999 | 100 | 1999 |
| Conocimiento del cáncer de mama y cáncer de mama hereditario en el personal de enfermería de un hospital público CMD Prolla, PS Silva, CBO Netto, JR Goldim, P Ashton-Prolla Revista latino-americana de enfermagem 23, 90-97, 2015 | 98 | 2015 |
| Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice B Leroy, ML Ballinger, F Baran-Marszak, GL Bond, A Braithwaite, ... Cancer research 77 (6), 1250-1260, 2017 | 90 | 2017 |
| Impact of β1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy A Biolo, N Clausell, KG Santos, R Salvaro, P Ashton-Prolla, A Borges, ... The American journal of cardiology 102 (6), 726-732, 2008 | 87 | 2008 |
| Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? MIW Achatz, P Hainaut, P Ashton-Prolla The lancet oncology 10 (9), 920-925, 2009 | 83 | 2009 |
| TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li–Fraumeni syndrome: impact on age at first diagnosis V Marcel, EI Palmero, P Falagan-Lotsch, G Martel-Planche, ... Journal of medical genetics 46 (11), 766-772, 2009 | 82 | 2009 |
| The germline mutational landscape of BRCA1 and BRCA2 in Brazil EI Palmero, DM Carraro, B Alemar, MAM Moreira, A Ribeiro-dos-Santos, ... Scientific reports 8 (1), 9188, 2018 | 80 | 2018 |
| PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines P Izetti, A Hautefeuille, AL Abujamra, CB de Farias, J Giacomazzi, ... Investigational new drugs 32, 783-794, 2014 | 78 | 2014 |
| Prevalence of the TP53 p. R337H mutation in breast cancer patients in Brazil J Giacomazzi, MS Graudenz, CABT Osorio, P Koehler-Santos, EI Palmero, ... PloS one 9 (6), e99893, 2014 | 72 | 2014 |
| miRNA-21 and miRNA-34a are potential minimally invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma B Alemar, P Izetti, C Gregorio, GS Macedo, MAA Castro, AB Osvaldt, ... Pancreas 45 (1), 84-92, 2016 | 71 | 2016 |
